newsevent

HTuO Biosciences’ poster - AtomForge: A novel polarizable and reactive force field for commercial scale applications - has been accepted at the American Chemical Society Meeting, August 13 - 17, 2023.

newsevent

Our CEO, Dr. Anthony Fejes, and Director of Business Development, Mr. Jacek Mis, will be in Boston, June 5-8 at the 2023 BIO International Convention. Connect with us through the partnering portal or email us directly to learn about our technology and its therapeutic potential.

newsevent

We have just released our first white paper, which describes the development of our technology - “Proof of Concept of AtomForge: A Novel Polarizable and Reactive Force Field.” Please email us at info@htuobio.com if you want to read it.

newsevent

HTuO Biosciences will be presenting at Life Science BC’s Invest in the West, sponsored by Lumira Ventures. Find us in session 8, where our CEO, Dr. Anthony Fejes, will be presenting and participating in a live Q&A session hosted by LDV Partners.

newsevent

HTuO Biosciences will be attending the digital partnering component of BIO Europe 2022. If you are in the business of optimizing drugs, we would like to connect with you. Please find us through the partnering platform or email us directly at info@htuobio.com to schedule a meeting.

newsevent

HTuO’s CEO, Dr. Anthony Fejes, participated in a panel discussion on Investing in Life Sciences and Healthtech, hosted by Vantec Angel Network.

newsevent

HTuO Biosciences will be attending BIO-Europe Spring. Please contact us at info@htuobio.com to set up a partnering meeting.

newsevent

HTuO Biosciences participated in the Diagnostics, Digital Health and Therapeutics session at the Invest in the West conference, presented by Amplitude Ventures.

newsevent

HTuO Biosciences participated in the Bio@JPB partnering event.

newsevent

HTuO Biosciences participated in the Valhalla Investors Summit BC Final, presenting as one of the top five companies

newsevent

HTuO Biosciences presented at the 2021 LSBC Invest in BC event, sponsored by Lumira Ventures.

newsevent

HTuO Biosciences presented at Angel Forum Virtual Meetup

newsevent

Continuing our progress in the Valhalla Investors Summit BC, HTuO has been named as one of the top 5 companies, and has progressed to the final, due diligence round.

newsevent

After a tough round of pitches and questions at the Valhalla Investors Summit BC, HTuO Biosciences is thrilled to advance on as one of the Top 11 Startups.

newsevent

HTuO Biosciences has been chosen as one of the top 20 companies to join the Valhalla Investment Summit BC 2021 cohort.

newsevent

We are thrilled to announce that we have successfully closed the first tranche of our pre-seed round. With help from our co-lead investors VANTEC Entrepreneurs (VCC) Fund Inc., in Canada and SWAN Venture Fund, in the USA, we have received over $700,000 USD (out of $1M USD allotted for the round) from investors in Canada, the USA, and Europe. The funds will allow us to expand our team, in order to move our proof of concept to commercialization and ensure the continued operations of our business.

newsevent

HTuO Biosciences has been chosen to participate in the Life Sciences British Columbia Investor Readiness Program’s fall 2021 cohort.

newsevent

HTuO Biosciences mentioned as one of the six companies to watch for in the Vancouver Tech Journal.

newsevent

HTuO Biosciences has been selected to present at the VANTEC Meeting: Investing in Life Sciences and HealthTech.

newsevent

HTuO Biosciences has been selected to present at the next Vantec Life Science Vantec Meeting.

newsevent

HTuO Biosciences has been selected to present at Tie Vancouver’s Demo Day, on April 8th, 2021.